The European Commission has tasked the Avicenna Alliance with meeting a significant challenge – developing recommendations and plans for the implementation of the Avicenna Roadmap in policy.
The Policy Development Working Group aims to work towards the inclusion of Avicenna Alliance members’ interests in EU policies. Many EU policies, Directives and Regulations predate the existence of the very same in silico technologies they are designed to govern. 
In order for the in silico market and research community to be enabled, current policies and legislations governing healthcare need to be updated. The creation of a framework for the validation of in silico models and the acceptance in the Regulatory system of data derived from modelling and simulation is a prerequisite for further investment in this field and the realization of its potential.

The Policy Working Group Mission is to work towards:

Ensuring a forward-looking policy framework to facilitate the large scale deployment of in silico technology and their acceptance by health authorities.

To significantly reducing time and cost for health care technologies approval and reimbursement and fostering medical innovation, including for those conditions with pressing unmet medical needs such as rare diseases and pediatric applications.

By combining the expertise and experience of Avicenna members to continuously:

  • inform European and US authorities about the benefits brought by in silico medicine;
  • advocate for the inclusion of CM&S (Computer Modelling and Simulation) in legislation, policy guidelines and research funds;
  • collaborate with health care stakeholders on in silico guidance and CM&S benefits dissemination, ensuring that in silico clinical trials become a pillar of medical device and drug development programs, when appropriate.

 

Priorities in 2019 and 2020

Following the adoption of the 2019-2021 Strategy, the next year activities will be dedicated to deliver the following projects, which reflect the legislative opportunities at EU level:

→ Position paper on paediatrics;
→ Position paper on orphan medicines;
→ Promotion of GSP vis-à-vis European policy-makers;
→ Advocating for a public consultation which would clarify the current policy landscape and next steps for in silico medicine in Europe.
 

Working group leader:

  • Dr. Emmanuelle Voisin
  • Founder and CEO
  • Voisin Consulting Life Sciences (VCLS)

Avicenna Alliance news

The EESC calls for the creation of Good Simulation Practices

The European Economic and Social Affairs Committee (EESC) has specifically called for the creation of Good Simulation Practices as part...

find out more ›

Avicenna continues to grow by welcoming Altair among its members!

The Avicenna Alliance is proud to announce the newest addition to its list of members: Altair!

Altair is a global technology...

find out more ›

Avicenna provides feedback on the processing of personal health data in the EU

During the month of July, the Avicenna Alliance received the opportunity to provide its contribution to the European...

find out more ›

The European Medicines Agency has accepted the Avicenna Alliance's request to be directly involved in Agency activities

We are proud to announce that the European Medicines Agency (EMA) has accepted...

find out more ›

The Avicenna Alliance provided feedback on the Pharmaceutical Strategy for Europe

We are proud to announce that the Avicenna Alliance has submitted Members’ feedback to the European Commission’s...

find out more ›

Show all activites

Sign up for our monthly newsletter!


Sign up